TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2889654

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% Ophthalmic Solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31721425

Group type: EXPERIMENTAL
Intervention: MINDBODYSTRONG program (cognitive behavioral skill-building program)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Attention control group (debriefing sessions)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: MINDBODYSTRONG program
Number of subjects: 89
Study: 28746977

Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil/folinic acid (FUFA) chemotherapy
Number of subjects: 3239

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: High stromal proportion (≥65%)
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: KRAS mutation with high stromal proportion
Number of subjects: 3239
Study: 27388615

Group type: EXPERIMENTAL
Intervention: losartan 100 mg once daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: spironolactone 25 mg once daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study: 24402842

Group type: EXPERIMENTAL
Intervention: Perioperative synbiotics
Number of subjects: 42

Group type: COMPARATOR
Intervention: No synbiotics (control group)
Number of subjects: 42
Study: 23640393

Group type: EXPERIMENTAL
Intervention: BOMP (bleomycin 7 mg days 1‐5, vincristine 0.7 mg m(‐2) day 5, mitomycin 7 mg m(‐2) day 5, cisplatin 14 mg m(‐2) days 1‐5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: RS alone (RS group)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: NACT group
Number of subjects: 134
Study: 20689583

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PQP); adults: 40 mg/320 mg; children: 20 mg/160 mg; n = 769
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Artesunate-mefloquine (AS+MQ); AS: 50 mg, MQ: 250 mg; n = 381
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA/PQP)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Artesunate-mefloquine (AS+MQ)
Number of subjects: 1150
Study: 18254893

Group type: EXPERIMENTAL
Intervention: VIP (8 pmol kg(‐1) min(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16356539

Group type: EXPERIMENTAL
Intervention: sCD40L in PAD patients with lengths >5 cm (N=38)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: sCD40L in PAD patients with lengths < or = 5 cm (N=25)
Number of subjects: 63

Group type: COMPARATOR
Intervention: sCD40L in control subjects (N=30)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MCP-1 in PAD patients with lengths >5 cm (N=38)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MCP-1 in PAD patients with lengths < or = 5 cm (N=25)
Number of subjects: 63

Group type: COMPARATOR
Intervention: MCP-1 in control subjects (N=30)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: hs-CRP in PAD patients with lengths >5 cm (N=38)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: hs-CRP in PAD patients with lengths < or = 5 cm (N=25)
Number of subjects: 63

Group type: COMPARATOR
Intervention: hs-CRP in control subjects (N=30)
Number of subjects: 63
Study: 14552594

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine eye drops given twice daily for 30 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study: 10975179

Group type: EXPERIMENTAL
Intervention: Performance monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Team self‐correction
Number of subjects: 0
Study: 9123927

Group type: EXPERIMENTAL
Intervention: Neocyte transfusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard red cell transfusion
Number of subjects: 18
Study: 1613672

Group type: EXPERIMENTAL
Intervention: VaxSyn HIV-1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alum adjuvant
Number of subjects: 12
Study: 382906

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31967736

Group type: EXPERIMENTAL
Intervention: Collagen combination material (collagen cone and collagen membrane)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study: 31753009

Group type: EXPERIMENTAL
Intervention: 6 mg nicotine gum
Number of subjects: 240

Group type: COMPARATOR
Intervention: 4 mg nicotine gum
Number of subjects: 240
Study: 28088030

Group type: EXPERIMENTAL
Intervention: linagliptin 5mg qd
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: metformin 500mg bid
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: metformin 1000mg bid
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: linagliptin 2.5mg/metformin 500mg bid
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: linagliptin 2.5mg/metformin 1000mg bid
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: linagliptin 2.5mg/metformin 1000mg bid (severe hyperglycemia group)
Number of subjects: 733

Group type: COMPARATOR
Intervention: linagliptin 5mg qd (severe hyperglycemia group)
Number of subjects: 733
Study: 25414262

Group type: EXPERIMENTAL
Intervention: AL-IVM1 (AL plus single dose of ivermectin 200 µg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AL-IVM2 (AL plus repeated dose of ivermectin 200 µg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (AL plus placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IVM (Ivermectin)
Number of subjects: 120
Study: 23552714

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 206

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 206
Study: 21809664

Group type: EXPERIMENTAL
Intervention: Systemic chemo-infusion with oxaliplatin (FOLFOX)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Regional chemo-infusion with irinotecan (FOLFIRI)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Systemic chemo-infusion
Number of subjects: 162

Group type: COMPARATOR
Intervention: Regional chemo-infusion
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 162
Study: 19728751

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg once daily for 10 days followed by 10 mg once daily for 10 days, along with aspirin 75 mg daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg maintenance dosing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg maintenance dosing
Number of subjects: 32
Study: 16961674

Group type: EXPERIMENTAL
Intervention: Specific anticoagulant prescription forms
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Usual prescribing practices (Control)
Number of subjects: 1469
Study: 16146551

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 8-12 ng/mL (GI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 15-20 ng/mL (GII)
Number of subjects: 70
Study: 12966414

Group type: EXPERIMENTAL
Intervention: Irinotecan 200 mg/m² i.v. (1-h infusion) on day 1, L-leucovorin 250 mg/m² i.v. (1-h infusion) plus 5-fluorouracil 850 mg/m² i.v. bolus on day 2 every 2 weeks (IRIFAFU)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 108
Study: 10218721

Group type: EXPERIMENTAL
Intervention: Temocapril 20 mg daily (n = 19)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 30
Study: 7611316

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity between 20/50 and 20/80
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity between 20/25 and 20/40
Number of subjects: 35
Study: 2095610

Group type: EXPERIMENTAL
Intervention: butamirate citrate linctus (Sinecod, Zyma)
Number of subjects: 60

Group type: COMPARATOR
Intervention: clobutinol syrup (Silomat, Boehringer, Ingelheim)
Number of subjects: 60
Study: 508075

Group type: EXPERIMENTAL
Intervention: Positional feedback stimulation training (PFST) in addition to conventional treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study: 31591187

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitor palbociclib and fulvestrant
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Loss of NF1
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: NF1 mutations
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: HER2, AKT1, NF1 mutations
Number of subjects: 210
Study: 29641247

Group type: EXPERIMENTAL
Intervention: Capsella bursa‐pastoris capsules (dosage: 2 capsules every 12 hours)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Mefenamic acid (500 mg, dosage: 2 capsules every 8 hours) + placebo
Number of subjects: 84
Study: 29207980

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavior therapy (CaCBTp), 12 weekly sessions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavior therapy (CaCBTp)
Number of subjects: 36
Study: 26255892

Group type: EXPERIMENTAL
Intervention: Cefepime and amoxicillin/clavulanic acid combination therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tigecycline-based therapy
Number of subjects: 51
Study: 24079038

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (50 f.Lg Bid)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (50 f.Lg Bid) and Totropiumi (18 f.Lg Qd)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Single group)
Number of subjects: 30
Study: 20417012

Group type: EXPERIMENTAL
Intervention: 3-dimensional (3D) miniplate fixation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Champy's miniplate fixation
Number of subjects: 20
Study: 18818386

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA; n = 22)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Successful Aging health educational control (SA; n = 20)
Number of subjects: 52
Study: 15990739

Group type: EXPERIMENTAL
Intervention: Endovascular implantation of a Medtronic Talent stent graft adjunctive to best medical treatment
Number of subjects: 136

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 136
Study: 12551865

Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg single oral dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (healthy non-smokers)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 14
Study: 10097929

Group type: EXPERIMENTAL
Intervention: Mix25 insulin (36 ± 4 U)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 30/70 insulin
Number of subjects: 22

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 22
Study: 8906292

Group type: EXPERIMENTAL
Intervention: Combination of MAOIs-A/B with 5-HTP
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-HTP alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAOIs-A/B alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 1867971

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic prophylaxis
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 138
Study: 7133792

Group type: EXPERIMENTAL
Intervention: Partial plasma exchange
Number of subjects: 94

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 94
Study: 31165606

Group type: EXPERIMENTAL
Intervention: Phone group (6-month home-based phone surveillance program with 12 scheduled phone calls every fortnight)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Phone group (6-month home-based phone surveillance program)
Number of subjects: 84
Study: 31088188

Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg/day
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 24464328

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25050518

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1,500 mg/day in 3 divided doses; n=19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between Curcuminoids and Placebo
Number of subjects: 40
Study: 24447437

Group type: EXPERIMENTAL
Intervention: Seven-valent pneumococcal conjugate vaccine (PCV-7)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 200
Study: 22933671

Group type: EXPERIMENTAL
Intervention: Intra-articular viscoseal instillation (13 men and 3 women)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Arthroscopic ACL reconstruction alone (15 men and 1 woman)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intra-articular viscoseal instillation
Number of subjects: 32
Study: 19567453

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 476

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 476
Study: 18604047

Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Labetalol (0.25 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal Saline (placebo)
Number of subjects: 90
Study: 15028356

Group type: EXPERIMENTAL
Intervention: Anterior fat pad preservation (group A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Anterior fat pad dissection (group B)
Number of subjects: 55
Study: 10932030

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study: 9048390

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 437

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (Control)
Number of subjects: 437
Study: 8342183

Group type: EXPERIMENTAL
Intervention: Intravenous glycerol (500 mL of 10% glycerol in saline over 4 hours on 6 consecutive days)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo treatment (saline)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intravenous glycerol
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 113
Study: 3730726

Group type: EXPERIMENTAL
Intervention: Axis-to-axis extrapolation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Line-to-axis extrapolation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Axis-to-line extrapolation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Older children (nine-year-olds)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Non-perpendicular lines
Number of subjects: 32
Study: 30475014

Group type: EXPERIMENTAL
Intervention: Active (adaptive) training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (nonadaptive) training
Number of subjects: 110
Study: 27716979

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with connective tissue graft
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified microsurgical tunnel technique (MMTT) with connective tissue graft
Number of subjects: 40
Study: 25028357

Group type: COMPARATOR
Intervention: IVB (1.25 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IVB+TRP (1.25 mg IVB combined with targeted retinal photocoagulation)
Number of subjects: 52
Study: 23084240

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 0.5 mg monthly (0.5q4)
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg monthly (2q4)
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 2 months after 3 initial monthly doses (2q8)
Number of subjects: 2419

Group type: COMPARATOR
Intervention: Monthly ranibizumab 0.5 mg (Rq4)
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: All aflibercept regimens
Number of subjects: 2419

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2419
Study: 20737113

Group type: EXPERIMENTAL
Intervention: Swimming group (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 61
Study: 18670833

Group type: EXPERIMENTAL
Intervention: Promotion-oriented messages
Number of subjects: 518

Group type: COMPARATOR
Intervention: Prevention-oriented messages
Number of subjects: 518
Study: 15770890

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy and combined chemoradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccines, antisense therapy, and proteasome inhibitors
Number of subjects: 0
Study: 12579101

Group type: EXPERIMENTAL
Intervention: Danaparoid (bolus of 40 U/kg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Heparin (bolus of 1 mg/kg)
Number of subjects: 71
Study: 11057100

Group type: EXPERIMENTAL
Intervention: Pokeweed (PWM) stimulation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin (PHA) stimulation
Number of subjects: 102
Study: 7590048

Group type: EXPERIMENTAL
Intervention: Initial flexible sigmoidoscopy plus air-contrast barium enema
Number of subjects: 149

Group type: COMPARATOR
Intervention: Initial colonoscopy
Number of subjects: 149
Study: 2177507

Group type: EXPERIMENTAL
Intervention: Systemic interferon and/or podophyllin treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Podophyllin and/or interferon
Number of subjects: 37
Study: 6996816

Group type: EXPERIMENTAL
Intervention: 500 mg BID cephradine
Number of subjects: 130

Group type: COMPARATOR
Intervention: 1000 mg BID cephradine
Number of subjects: 130
Study: 30628167

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (10 g d-1)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Whole grain (25 g d-1)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Nuts (30 g d-1)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Legumes (25 g d-1)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Fish (25 g d-1)
Number of subjects: 296
Study: 29580529

Group type: EXPERIMENTAL
Intervention: Extruded sorghum breakfast cereal combined with unfermented probiotic milk
Number of subjects: 0
Study: 27216350

Group type: EXPERIMENTAL
Intervention: oxymetazoline plus mometasone furoate nasal spray (MFNS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo plus mometasone furoate nasal spray (MFNS)
Number of subjects: 68
Study: 25109411

Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MDR1 C3435T polymorphisms (C/C, C/T, T/T)
Number of subjects: 24
Study: 22566413

Group type: EXPERIMENTAL
Intervention: Dietary counseling for mothers on breastfeeding and complementary feeding during the first year of infants' lives (n = 200)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (n = 300)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Dietary counseling for mothers (n = 200)
Number of subjects: 500
Study: 20485306

Group type: EXPERIMENTAL
Intervention: L4 diet (63.3% SFA/4.06% R-TFA)
Number of subjects: 111

Group type: COMPARATOR
Intervention: L0 diet (72% SFA/2.85% R-TFA)
Number of subjects: 111
Study: 17083910

Group type: EXPERIMENTAL
Intervention: 350 mm² Baerveldt glaucoma implant
Number of subjects: 212

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC)
Number of subjects: 212
Study: 16097647

Group type: EXPERIMENTAL
Intervention: Radionuclide cisternography with early bladder visualization and blood activity monitoring
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal pressure hydrocephalus (NPH) as control
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Blood radioactivity monitoring
Number of subjects: 9
Study: 12092940

Group type: EXPERIMENTAL
Intervention: Culturally specific sexual health intervention
Number of subjects: 218

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 218
Study: 9654221

Group type: EXPERIMENTAL
Intervention: Protocol A (400 msec cycle length, extrastimulus delivered once)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protocol B (400 msec cycle length, extrastimulus repeated three times)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protocol C (300 msec cycle length, no repetition of extrastimuli)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All protocols
Number of subjects: 30
Study: 7615107

Group type: EXPERIMENTAL
Intervention: Finasteride 7.5 mg/d for 9 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2385206

Group type: EXPERIMENTAL
Intervention: Golytely
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cascara-Salax
Number of subjects: 28
Study: 264923

Group type: EXPERIMENTAL
Intervention: Two fluoride tablets daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One fluoride tablet daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablet (control group)
Number of subjects: 0
Study: 6794081

Group type: EXPERIMENTAL
Intervention: Naloxone 1.6 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 12
Study: 30782937

Group type: EXPERIMENTAL
Intervention: Education about the risks of driving into floodwater plus a theory‐based behaviour change intervention using planning and imagery exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education about the risks of driving into floodwater
Number of subjects: 0
Study: 28872938

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Football
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Basketball
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 26741119

Group type: EXPERIMENTAL
Intervention: Sleep-Low (SL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 21
Study: 25632742

Group type: EXPERIMENTAL
Intervention: Wuji Powder (WP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aripiprazole (5 mg, once daily)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both WP and Aripiprazole
Number of subjects: 70